| 摘要 |
A method to a) determine the probability of a future occurrence of bone metastases in patients with primary carcinomas and, if appropriate, the necessity for prophylactic treatment that constitutes the perioperative determination of the content of BSP (bone sialoprotein) and/or OPN (osteopontin) or their fragments or isoforms from one or more body fluids using polyclonal or monoclonal antibodies; b) improve the differentiation of patients with multiple myeloma from healthy persons or osteoporotic patients, to determine the response of patients with multiple myeloma to specific therapy or treatments, and to predict the outcome of the disease or the survival of the patient with multiple myeloma, all of them characterized by the determination of the amount of BSP (bone sialoprotein) and/or OPN (osteopontin) or their fragments or isoforms from one or more body fluids, using polyclonal or monoclonal antibodies.
|
